Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism ...

Dr C Feinle, Gastroenterology Division, University Hospital Zurich, Rämistr. 100, 8091 Zurich, Switzerland. BACKGROUND/AIMS We aimed to evaluate the role of fat and cholecystokinin (CCK) in the ...

Inflammatory bowel disease and Parkinson’s disease are chronic progressive disorders that mainly affect different organs: the gut and brain, respectively. Accumulating evidence has suggested a ...

Objective We explored the hypothesis that TGR5, the bile acid (BA) G-protein-coupled receptor highly expressed in biliary epithelial cells, protects the liver against BA overload through the ...

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a ...

Cirrhotic portal hypertension is characterised by development of the decompensating events of ascites, encephalopathy, portal hypertensive bleeding and hepatorenal syndrome, which arise in a setting ...

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease which, if untreated, often leads to cirrhosis, liver failure and death. Major advances were made in its management based on ...

We read with great interest the article by Henniger et al 1 about reducing scope 3 carbon emissions in endoscopy and would like to discuss several points. First, we commend the study’s transparency, ...

Correspondence to Professor Maria Gloria Dominguez-Bello, Department of Biochemistry and Microbiology, Rutgers, the State University of New Jersey, New Brunswick, NJ 08901, USA; ...

Objective The microbiome contributes to the pathogenesis of inflammatory bowel disease (IBD) but the relative contribution of different lifestyle and environmental factors to the compositional ...

Objective To fulfil an unmet therapeutic need for treating type 2 diabetes by developing an innovative oral drug delivery nanosystem increasing the production of glucagon-like peptide-1 (GLP-1) and ...

1 University of Sheffield, School of Medicine and Biomedical Sciences, Academic Unit of Molecular and Clinical Pharmacology, The Royal Hallamshire Hospital, Sheffield, UK 2 Department of ...